Literature DB >> 20299964

Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China.

Lucette A Cysique1, Scott L Letendre, Christopher Ake, Hua Jin, Donald R Franklin, Saurabh Gupta, Chuan Shi, Xin Yu, Zunyou Wu, Ian S Abramson, Igor Grant, Robert K Heaton.   

Abstract

OBJECTIVE: To quantify and characterize the nature of cognitive change over 1 year in a cohort of HIV-positive former plasma donors in rural China.
DESIGN: The present study is an observational cohort study.
METHODS: One hundred and ninety-two HIV-positive and 101 demographically comparable HIV-negative individuals, all former plasma donors, who lived in a rural part of China, received comprehensive medical and neuropsychological examinations. At study entry, 56% of HIV-positive group was on combination antiretroviral treatment and 60.9% at follow-up. Multiple regression change score approach was used with the HIV-negative sample to develop norms for change that would be then applied to the HIV-positive participants. Follow-up test scores adjusted for the control group practice effect.
RESULTS: Fifty-three HIV-positive individuals (27%) developed significant cognitive decline as compared with five (5%) HIV-negative individuals. Cognitive decline was predicted at baseline by AIDS status, lower nadir CD4, and worse processing speed; at follow-up, it was associated with lower current CD4 cell count and failure of viral suppression on combination antiretroviral treatment. Neuropsychological decline also was associated with decreased independence in activities of daily living. Using neuropsychological impairment scores that were corrected for 'practice' on repeated testing, we found that among the decliners, 41.5% (N = 22) had incident impairment, whereas 38% (N = 20) declined within the impaired range and another 20.7% (N = 11) declined within the normal range.
CONCLUSION: The present study demonstrates that despite ongoing combination antiretroviral treatment, cognitive decline in HIV-positive people is common over a 1-year follow-up. Regression-based norms for change on western neuropsychological tests can be used to detect disease-related cognitive decline in a developing country.

Entities:  

Mesh:

Year:  2010        PMID: 20299964      PMCID: PMC2898923          DOI: 10.1097/QAD.0b013e32833336c8

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals.

Authors:  Alexander Collie; Paul Maruff; David G Darby; Michael McStephen
Journal:  J Int Neuropsychol Soc       Date:  2003-03       Impact factor: 2.892

2.  Normative data for determining significance of test-retest differences on eight common neuropsychological instruments.

Authors:  Andrew J Levine; Eric N Miller; James T Becker; Ola A Selnes; Bruce A Cohen
Journal:  Clin Neuropsychol       Date:  2004-08       Impact factor: 3.535

3.  Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals.

Authors:  M A Cole; J B Margolick; C Cox; X Li; O A Selnes; E M Martin; J T Becker; H A Aronow; B Cohen; N Sacktor; E N Miller
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

4.  Implications of within-person variability in cognitive and neuropsychological functioning for the interpretation of change.

Authors:  Timothy A Salthouse
Journal:  Neuropsychology       Date:  2007-07       Impact factor: 3.295

5.  Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.

Authors:  J J Sevigny; S M Albert; M P McDermott; J C McArthur; N Sacktor; K Conant; G Schifitto; O A Selnes; Y Stern; D R McClernon; D Palumbo; K Kieburtz; G Riggs; B Cohen; L G Epstein; K Marder
Journal:  Neurology       Date:  2004-12-14       Impact factor: 9.910

6.  Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients.

Authors:  Lucette A Cysique; Bruce J Brew; Mark Halman; Jose Catalan; Ned Sacktor; Richard W Price; Steve Brown; J Hampton Atkinson; David B Clifford; David Simpson; Gabriel Torres; Colin Hall; Christopher Power; Karen Marder; Justin C McArthur; William Symonds; Carmen Romero
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-01       Impact factor: 3.731

7.  Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

Authors:  Valerio Tozzi; Pietro Balestra; Rita Bellagamba; Angela Corpolongo; Maria Flora Salvatori; Ubaldo Visco-Comandini; Chrysoula Vlassi; Marinella Giulianelli; Simonetta Galgani; Andrea Antinori; Pasquale Narciso
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

8.  Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death.

Authors:  N C Sacktor; H Bacellar; D R Hoover; T E Nance-Sproson; O A Selnes; E N Miller; G J Dal Pan; C Kleeberger; A Brown; A Saah; J C McArthur
Journal:  J Neurovirol       Date:  1996-12       Impact factor: 2.643

9.  Detecting change: A comparison of three neuropsychological methods, using normal and clinical samples.

Authors:  R K Heaton; N Temkin; S Dikmen; N Avitable; M J Taylor; T D Marcotte; I Grant
Journal:  Arch Clin Neuropsychol       Date:  2001-01       Impact factor: 2.813

10.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01
View more
  35 in total

1.  Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults.

Authors:  Andrew J Levine; Susan Service; Eric N Miller; Sandra M Reynolds; Elyse J Singer; Paul Shapshak; Eileen M Martin; Ned Sacktor; James T Becker; Lisa P Jacobson; Paul Thompson; Nelson Freimer
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-24       Impact factor: 3.568

2.  APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors.

Authors:  Stephen A Spector; Kumud K Singh; Saurabh Gupta; Lucette A Cystique; Hua Jin; Scott Letendre; Rachel Schrier; Zunyou Wu; Kun X Hong; Xin Yu; Chuan Shi; Robert K Heaton
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

3.  Neuropsychological test performance among healthy persons in northern India: development of normative data.

Authors:  Drenna Waldrop-Valverde; Raymond L Ownby; Deborah L Jones; Sunil Sharma; Ritu Nehra; Adarsh M Kumar; Sudesh Prabhakar; Mahendra Kumar
Journal:  J Neurovirol       Date:  2015-03-18       Impact factor: 2.643

4.  The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to tobacco smokers without HIV.

Authors:  Joseph D Harrison; Jessica A Dochney; Sonja Blazekovic; Frank Leone; David Metzger; Ian Frank; Robert Gross; Anita Hole; Karam Mounzer; Steven Siegel; Robert A Schnoll; Rebecca L Ashare
Journal:  J Neurovirol       Date:  2017-04-20       Impact factor: 2.643

5.  Absence of neurocognitive impairment in a large Chinese sample of HCV-infected injection drug users receiving methadone treatment.

Authors:  Saurabh Gupta; Jennifer E Iudicello; Chuan Shi; Scott Letendre; Adam Knight; Jianhua Li; Patricia K Riggs; Donald R Franklin; Nichole Duarte; Hua Jin; J Hampton Atkinson; Xin Yu; Zunyou Wu; Igor Grant; Robert K Heaton
Journal:  Drug Alcohol Depend       Date:  2014-01-13       Impact factor: 4.492

6.  One-year stability of prospective memory symptoms and performance in aging and HIV disease.

Authors:  Victoria M Kordovski; Kelli L Sullivan; Savanna M Tierney; Steven Paul Woods
Journal:  J Clin Exp Neuropsychol       Date:  2019-11-07       Impact factor: 2.475

7.  Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities.

Authors:  Laura M Campbell; Christine Fennema-Notestine; Rowan Saloner; Mariam Hussain; Anna Chen; Donald Franklin; Anya Umlauf; Ronald J Ellis; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Ned Sacktor; Susan Morgello; J Allen McCutchan; Scott Letendre; Igor Grant; Robert K Heaton
Journal:  J Int Neuropsychol Soc       Date:  2019-10-02       Impact factor: 2.892

Review 8.  HIV and Aging in Mainland China: Implications for Control and Prevention Research.

Authors:  Na He; Yingying Ding; Jing Li; Shiying Yuan; Lulu Xu; Shijie Qiao; Xiaohui Xu; Bowen Zhu; Ruizi Shi; John P Barile; Frank Y Wong
Journal:  Curr HIV/AIDS Rep       Date:  2019-12       Impact factor: 5.071

Review 9.  Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use.

Authors:  Jody Kamminga; Luxshimi Lal; Edwina J Wright; Mark Bloch; Bruce J Brew; Lucette A Cysique
Journal:  Curr HIV/AIDS Rep       Date:  2017-06       Impact factor: 5.071

10.  The effects of antiretroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India.

Authors:  Manisha Ghate; Sanjay Mehendale; Rachel Meyer; Anya Umlauf; Reena Deutsch; Rujvi Kamat; Madhuri Thakar; Arun Risbud; Smita Kulkarni; Maiko Sakamoto; Terry Alexander; Donald Franklin; Scott Letendre; Robert K Heaton; Igor Grant; Thomas D Marcotte
Journal:  J Neurovirol       Date:  2015-03-07       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.